• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Portal Hypertension - Pipeline Review, H2 2011 - Product Image

Portal Hypertension - Pipeline Review, H2 2011

  • Published: August 2011
  • 32 pages
  • Global Markets Direct

Portal Hypertension - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Portal Hypertension - Pipeline Review, H2 2011', provides an overview of the Portal Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Portal Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Portal Hypertension. 'Portal Hypertension - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Portal Hypertension.
- A review of the Portal Hypertension products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Portal Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Portal Hypertension
Portal Hypertension Therapeutics under Development by Companies
Portal Hypertension Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Portal Hypertension Therapeutics - Products under Development by Companies
Portal Hypertension Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Portal Hypertension Therapeutics Development
Dong-A Pharmaceutical Co., Ltd.
Chiasma (Israel) ltd.
Portal Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Zydena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Octreolin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Propranolol + Norfloxacin + VSL#3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Somatostatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Portal Hypertension Therapeutics – Drug Profile Updates
Portal Hypertension Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Portal Hypertension, H2 2011
Products under Development for Portal Hypertension – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Dong-A Pharmaceutical Co., Ltd., 2011
Chiasma (Israel) ltd., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Portal Hypertension Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Portal Hypertension, H2 2011
Products under Development for Portal Hypertension – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos